Pfizer Inc dividend calculator – Pfizer Yields 5.92% Following 2.4% Dividend Increase: Here’s Why Investors Should Buy In
December 27, 2023
☀️Trending News
Pfizer Inc ($NYSE:PFE)., one of the world’s largest pharmaceutical companies, has recently announced a 2.4% dividend increase which has pushed their yield to 5.92%. This makes it an attractive investment opportunity for investors. Pfizer Inc. is a global leader in the discovery, development, and manufacture of healthcare products, including prescription medicines, vaccines, biologics, and consumer healthcare products. The company’s strong financial performance and consistent dividend payments make it an attractive investment option for income-seeking investors.
Additionally, Pfizer Inc. is also trading at a discount which could potentially reward long-term investors with capital appreciation over the long run. Given the above factors, investors should consider buying into Pfizer Inc. following the 2.4% dividend increase that has pushed the company’s yield to 5.92%. Not only is this an attractive investment opportunity with potential for steady income, but also offers long-term capital appreciation potential.
Dividends – Pfizer Inc dividend calculator
Pfizer Inc has been steadily providing a steady yield to investors over the last three years, as they have issued annual dividend per share of 1.63, 1.6, and 1.56 USD. This trend looks set to continue as dividend yields from 2021 to 2023 are expected to be 3.75%, 3.22%, and 3.83%, respectively. On average, this works out to an impressive 3.6% yield for investors. For those looking for a reliable dividend stock, Pfizer Inc is certainly worth a look. With a long-term track record of consistently providing a healthy dividend yield, it is a safe bet for those looking for the stability that comes with a dividend stock.
Additionally, with the expected growth in the upcoming years, it could be an excellent choice for those looking to benefit from a rising stock price while also receiving a steady income from dividends.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Pfizer Inc. More…
| Total Revenues | Net Income | Net Margin |
| 68.54k | 10.48k | 18.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pfizer Inc. More…
| Operations | Investing | Financing |
| 29.27k | -15.78k | -14.83k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pfizer Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 197.21k | 101.29k | 16.94 |
Key Ratios Snapshot
Some of the financial key ratios for Pfizer Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 12.1% | -6.5% | 17.9% |
| FCF Margin | ROE | ROA |
| 38.0% | 8.0% | 3.9% |
Analysis
We at GoodWhale have conducted an in-depth analysis of Pfizer Inc.’s fundamentals, as can be seen on our Star Chart. We conclude that the company is strong in dividend and profitability, and medium in asset, but weak in growth. The company has a high health score of 8/10, which means that it is capable of riding out any crisis without the risk of bankruptcy. We have also classified Pfizer Inc. as a ‘cow’, which denotes that the company has a track record of paying out consistent and sustainable dividends. This makes Pfizer Inc. an attractive option for investors seeking steady returns and income in the form of dividends. Value investors and income investors are likely to be interested in such a company. The Star Chart rating of PFIZER INC also provides a comprehensive overview of the financial health of the company which can be relied upon to make an informed decision about investing in the company. More…
Peers
In the pharmaceutical industry, competition is fierce between companies striving to bring innovative new drugs to market. Among the leaders in this industry are Pfizer Inc and its competitors Astellas Pharma Inc, Roche Holding AG, and AstraZeneca PLC. While each company has its own strengths and weaknesses, they all share a commitment to research and development in an effort to stay ahead of the competition.
– Astellas Pharma Inc ($TSE:4503)
Astellas Pharma Inc is a Japanese pharmaceutical company with a market cap of 3.61T as of 2022. The company’s ROE is 6.6%. Astellas Pharma is engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company’s products include ethical drugs, over-the-counter drugs, and generic drugs. Astellas Pharma also has a clinical research division that conducts clinical trials of new drugs.
– Roche Holding AG ($OTCPK:RHHBY)
Roche Holding AG is a multinational pharmaceutical company headquartered in Basel, Switzerland. The company was founded in 1896 by Fritz Hoffmann-La Roche. Roche is the world’s largest biotech company, with products in the areas of pharmaceuticals, diagnostics, and consumer health. The company’s mission is to “improve lives by enabling people to do more, feel better, and live longer.”
Roche Holding AG has a market cap of 270.34B as of 2022, a Return on Equity of 47.83%. The company’s strong market position and financial performance are due to its innovative products and services, which address a broad range of medical needs. Roche is committed to research and development, and has a strong pipeline of new products in development. The company’s focus on customer needs and its ability to bring new products to market quickly have resulted in strong financial performance and shareholder value.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a pharmaceutical company with a market cap of 152.81 billion as of 2022. The company has a return on equity of -0.94%. AstraZeneca PLC is engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and biologic products for the treatment of cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory diseases.
Summary
Investors looking for a steady income stream may be wise to consider Pfizer Inc (PFE), as the company recently announced a 2.4% dividend increase, raising its yield to 5.92%. Analysts have given the company favorable ratings and suggest that the stock has potential for further growth. Pfizer is considered a defensive stock, meaning it provides steady returns and can weather turbulent market conditions. Investment analysts note that the stock has strong fundamentals and is well-positioned for future growth, yet is currently trading at a discount.
Pfizer has seen consistent earnings growth in the past few years and has a strong balance sheet. The company has a diversified portfolio of products and the potential for additional income through continued product development. Overall, Pfizer is an attractive option for investors looking for a steady income stream and long-term growth potential.
Related Posts
Recent Posts
